Multitarget Anticancer Activity of Pyrazoline‐Based Hybrids: Insights into Apoptosis, Bovine Serum Albumin/DNA Interactions, and Caspase Targeting
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500646 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Milena M Petrović und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, University of Kragujevac, R. Domanovica 12, 34000, Kragujevac, Serbia. Hauptthemen laut MEDLINE: Apoptosis, Serum Albumin, Bovine, Antineoplastic Agents, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Ministry of Science, Technological Development and Innovation of the Republic of Serbia.
Abstract (Originalsprache)
A series of novel pyrazoline‐based hybrids, bearing a pyrrole or indole scaffold, is designed, synthesized, and evaluated for anticancer potential. MTT assay reveals 4′a , 4′c , and 4′e as promising cytotoxic agents, where 4′e possess good pharmacological profile exhibiting prominent potency toward tumor cell lines HeLa, K562, and HL‐60 (IC 50 = 3.7–5.1 µM), and selectivity toward normal MRC‐5 cell line (IC 50 > 50 µM). Apoptosis induction is confirmed for all three compounds, with 4′e activating both caspase‐3 and caspase‐9 demonstrating a dual apoptotic mechanism. Molecular docking supports these findings, revealing a strong binding affinity of 4′e toward both caspases. Interaction with bovine serum albumin (BSA) is confirmed by fluorescence quenching and docking, indicating specific site binding and potential impact on pharmacokinetics. In addition, Förster resonance energy transfer (FRET) analysis provides valuable insight into the binding interaction between the investigated complexes and BSA. DNA‐binding studies demonstrate that 4′e preferentially binds within the minor groove, while docking also suggests intercalative potential, which is further supported by viscosity measurements, confirming its ability to modulate DNA‐dependent apoptotic signaling via intercalative binding. These results highlight compound 4′e as a promising anticancer candidate with selective cytotoxicity and multitarget engagement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Science, University of Kragujevac, R. Domanovica 12, 34000, Kragujevac, Serbia.
- Department of Science, Institute for Information Technologies, University of Kragujevac, Jovana Cvijića bb, 34000, Kragujevac, Serbia.
- Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000, Belgrade, Serbia.
ORCID-Profile: Milena M Petrović
Förderung
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia
Zitieren
APA
Petrović, M. M., Andrejević, T., Milanović, Ž., Milisavljević, K., Stanojković, T., Žižak, Ž., & Marković, V. (2025). Multitarget Anticancer Activity of Pyrazoline‐Based Hybrids: Insights into Apoptosis, Bovine Serum Albumin/DNA Interactions, and Caspase Targeting. ChemMedChem. https://doi.org/10.1002/cmdc.202500646
Vancouver
Petrović MM, Andrejević T, Milanović Ž, Milisavljević K, Stanojković T, Žižak Ž, et al. Multitarget Anticancer Activity of Pyrazoline‐Based Hybrids: Insights into Apoptosis, Bovine Serum Albumin/DNA Interactions, and Caspase Targeting. ChemMedChem. 2025. doi:10.1002/cmdc.202500646
BibTeX
@article{Petrovi2025,
author = {Petrović, Milena M and Andrejević, Tina and Milanović, Žiko and Milisavljević, Kristina and Stanojković, Tatjana and Žižak, Željko and Marković, Violeta},
title = {Multitarget Anticancer Activity of Pyrazoline‐Based Hybrids: Insights into Apoptosis, Bovine Serum Albumin/DNA Interactions, and Caspase Targeting},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500646}
}
EUVIMED